Company profile: Progenics Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
Products and services
- PNT2003: A somatostatin receptor-targeted 177Lu radioligand therapy for gastroenteropancreatic neuroendocrine tumors, currently in the regulatory filing stage
- PNT2002: A small-molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 3 clinical trials
- LNTH-1404: A Tc-99m-labeled molecule used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer and metastases, currently in Phase 3 clinical trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Progenics Pharmaceuticals
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
Apceth Biopharma
HQ: Germany
Website
- Description: Provider of GMP-compliant contract development and manufacturing services for complex cell and gene therapy products (ATMPs). Services include GMP manufacturing for clinical and commercial therapies, process development and optimization, analytical testing and quality control, cell therapy consulting, QP batch certification and EU import, supported by GMP facilities across North America, Europe, and Asia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apceth Biopharma company profile →
Gloucester Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development, acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization; owned by Celgene. Its first compound, romidepsin, is a late-stage oncology drug candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gloucester Pharma company profile →
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
Mevion Medical Systems
HQ: United States
Website
- Description: Provider of innovative, safe, and effective radiation therapy solutions for the treatment of cancer, pioneering modern proton therapy systems and transforming advances in medical technology and science into practical clinical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mevion Medical Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Progenics Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Progenics Pharmaceuticals
2.2 - Growth funds investing in similar companies to Progenics Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Progenics Pharmaceuticals
4.2 - Public trading comparable groups for Progenics Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →